Proposed generics from Apotex Inc. and Sandoz Inc. of the skin infection and bacterial pneumonia treatment Teflaro (ceftaroline fosamil for injection) will infringe patents covering the drug, according to a Jan. 5 lawsuit filed by Forest Laboratories (Forest Laboratories, LLC v. Apotex Corp.filed).
In the lawsuit, filed in the U.S. District Court for the District of Delaware, Forest asked the court to enjoin the companies from making and selling their generics of Teflaro before the patents they are challenging expire.
There are four patents at issue in the litigation: U.S. Patent No. 8,247,400 (Cephem compounds useful for the ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.